Government-Owned Inventions; Availability for Licensing, 10129-10130 [2015-03779]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 37 / Wednesday, February 25, 2015 / Notices
This information will help inform this
strategic planning process and provide
evidence to inform decisions on
potential investments in grants for
oncology nursing education in LMICs.
Additionally, this information will be
used in an online, interactive map that
is being developed by CGH which will
10129
than one response if they have up to
three projects.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
51.
allow external organizations, such as
cancer centers, to explore what projects
are being done in which countries,
which will facilitate collaborations and
minimize duplication. The frequency of
the data collection will be once per year
although respondents may have more
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Number of
respondents/
year
Number of
responses per
respondent
Average burden per response
(in hours)
Total annual
burden hours
Directors of Nursing .........................................................................................
68
3
15/60
51
Dated: February 19, 2015.
Karla Bailey,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 2015–03788 Filed 2–24–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
asabaliauskas on DSK5VPTVN1PROD with NOTICES
SUMMARY:
HbF Induction Therapy for Sickle Cell
Disease and Thalassemias
Description of Technology: Sickle cell
disease and thalassemia are hereditary
VerDate Sep<11>2014
19:36 Feb 24, 2015
Jkt 235001
disorders marked by the disruption in
the pathways responsible for carrying
oxygen to red blood cells. Symptoms
associated with these disorders include
anemia, jaundice, and severe pain. It has
been shown that mutations during the
development of fetal to adult
hemoglobin can contribute to a delay in
red blood cell maturity underlying
sickle cell disease. As a result, there has
been an increased focus on treatments
that promote the induction of fetal
hemoglobin (HbF) to improve clinical
symptoms and ameliorate the severity of
the diseases. Researchers at the National
Institute of Diabetes and Digestive and
Kidney Diseases have identified
methods of increasing fetal hemoglobin
by increasing the expression of Lin28 or
decreased expression of let-7 microRNAs. The lead inventor and colleagues
have developed novel lentiviral
expression vectors containing
hemoglobin regulators under the control
of erythroid-specific promoters that can
be used to increase Hbf expression
without affecting the maturity of red
blood cells. In addition, they have
found, through the use of tough decoy
inhibition of Let-7 micro-RNAs, a
selection of Let-7 genes with greater
involvement in HbF expression. This
technology could lead to development
of novel HbF induction therapies that
reactivate and reduce the aberrant
pathologies associated with human
sickle-cell anemia and beta thalassemia.
Potential Commercial Applications:
• Ex vivo and in vivo therapeutics for
treatment of sickle-cell anemia and beta
thalassemias.
• Potential use in combination with
other transduction methods for unique
therapeutic strategies.
Competitive Advantages:
• Reduced production of symptomassociated adult hemoglobin.
• Lin28 overexpression at defined
stage of hematopoietic cell
development.
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
• Therapeutic increases in patient
HbF expression at lower viral titers than
current direct transduction methods.
• Improved safety and reduced
toxicity as a result of erythroid-specific
expression.
Development Stage:
• Early-stage
• In vitro data available
• In vivo data available (animal)
Inventors: Jeffery L. Miller, Yuanwei
T. Lee, Jaira F. de Vasconcellos, Colleen
K. Byrnes (all of NIDDK)
Intellectual Property: HHS Reference
No. E–249–2014/0—US Provisional
Application No. 62/046,247 filed
September 5, 2014
Related Technology: HHS Reference
No. E–456–2013/2—PCT Application
No. PCT/US2013/067811 filed October
31, 2013, which published as WO 2014/
200557 on December 18, 2014
Licensing Contact: Vince Contreras,
Ph.D.; 301–435–4711; contrerasv@
mail.nih.gov
Collaborative Research Opportunity:
The National Institute of Diabetes and
Digestive and Kidney Diseases is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize this
technology. For collaboration
opportunities, please contact Marguerite
J. Miller at millermarg@niddk.nih.gov or
301–496–9003.
T Cell-Based Adoptive Transfer
Immunotherapy for PolyomavirusAssociated Pathologies
Description of Technology: Available
for licensing are methods to generate T
cells responsive to multiple
polyomaviruses. The resulting T cell
populations could be useful in treating
immunosuppressed individuals with
polyomavirus infections or
polyomavirus-associated pathologies
such as Merkel cell carcinoma (MCC),
polyomavirus-associated nephropathy
(PVAN), hemorrhagic cystitis,
E:\FR\FM\25FEN1.SGM
25FEN1
10130
Federal Register / Vol. 80, No. 37 / Wednesday, February 25, 2015 / Notices
progressive multifocal
leukoencephalopathy (PML), and
trichodysplasia spinulosa (TS). The
methods could also be used to restore
polyomavirus-specific immunity in
immunocompromised individuals.
Potential Commercial Applications:
Immunotherapy for immunosuppressed
individuals with polyomavirusassociated pathologies.
Competitive Advantages: Methods
allow development of polyomavirus
antigen-specific T cells.
Development Stage:
• Early-stage
• In vitro data available
Inventors: John A. Barrett (NHLBI),
Dhanalakshmi Chinnasamy (NHLBI),
Pawel J. Muranski (NHLBI), Christopher
B. Buck (NCI)
Intellectual Property: HHS Reference
No. E–166–2014/0—US Application No.
62/075,726 filed November 5, 2014
Related Technologies:
• HHS Reference No. E–168–2011
• HHS Reference No. E–549–2013
Licensing Contact: Patrick McCue,
Ph.D.; 301–435–5560; mccuepat@
od.nih.gov
Collaborative Research Opportunity:
The National Heart, Lung, and Blood
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize methods to generate T
cells responsive to multiple
polyomaviruses. For collaboration
opportunities, please contact Dr.
Vincent Kolesnitchenko at kolesniv@
nhlbi.nih.gov.
asabaliauskas on DSK5VPTVN1PROD with NOTICES
89Zr-Oxine
Complex for In Vivo PET
Imaging of Labelled Cells and
Associated Methods
Description of Technology: This
technology relates to a Zirconium-89
(89Zr)-oxine complex for cell labeling,
tracking of labeled cells by whole-body
positron emission tomography/
computed tomography (PET/CT)
imaging, and associated methods. A
long half-life of 89Zr (78.4 hours), high
sensitivity of PET and absence of
background signal in the recipient
enable tracking cells over a week using
low levels of labeling radioactivity,
without causing cellular toxicity. The
89Zr-oxine complex is synthesized
quickly by mixing components at room
temperature and produces high yields.
Cell labeling is achieved by a short,
room temperature incubation. The 89Zroxine complex is capable of labeling a
wide range of cell types of therapeutic
or pathogenic relevance (natural,
disease, engineered cells), independent
of factors such as cell cycle or receptor
expression. The label is retained during
VerDate Sep<11>2014
18:05 Feb 24, 2015
Jkt 235001
cell division. 89Zr-oxine labeled cells
can also be easily cross labeled (for
example, optically or magnetically) for
multi-modality imaging and analysis.
Labeled cell migration and kinetics can
be analyzed and quantified in vivo over
a week, improving research strategies
and ability to develop and improve cell
therapies and diagnostics.
Potential Commercial Applications:
Cell therapies and diagnostics.
Competitive Advantages: Simple
preparation, broadly applicable cell
label, high resolution imaging and
monitoring over period of a week, low
toxicity, easily combined with labeling
technologies and cell therapies.
Development Stage: In vivo data
available (animal).
Inventors: Noriko Sato (NCI), Haitao
Wu (NHLBI), Gary L. Griffiths (NCI),
Peter L. Choyke (NCI)
Publications:
1. Sato N, et al. Generation and use of
long-lasting cell labeling agent for
positron emission tomography (PET)
imaging. J Nucl Med. May 2014; 55
(Supplement 1):273.
2. Sato N, et al. 89Zr-oxine complex
positron emission tomography (PET)
cell imaging for monitoring cell-based
therapies. Radiology, 2015, In press.
Intellectual Property: HHS Reference
No. E–080–2014/0—US Patent
Application No. 61/973,706 filed April
1, 2014
Licensing Contact: Edward (Tedd)
Fenn; 424–297–0336; Tedd.fenn@
nih.gov
Collaborative Research Opportunity:
The National Cancer Institute is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize cell labeling, cell
tracking, cell trafficking, cell-based
therapy, PET imaging. For collaboration
opportunities, please contact John D.
Hewes, Ph.D. at john.hewes@nih.gov or
240–276–5515.
Dated: February 18, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–03779 Filed 2–24–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Autoimmunity Transplantation
Intolerance.
Date: March 11, 2015.
Time: 3:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Betty Hayden, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4206,
MSC 7812, Bethesda, MD 20892, 301–435–
1223, haydenb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Drug Discovery and Mechanisms of
Antimicrobial Resistance.
Date: March 13, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Guangyong Ji, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3211,
MSC 7808, Bethesda, MD 20892, 301–435–
1146, jig@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Skeletal
Muscle related SBIR/STTR.
Date: March 17, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Richard Ingraham, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4116,
MSC 7814, Bethesda, MD 20892, 301–496–
8551, ingrahamrh@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Program
Project: Regulation of Cell Survival and
Death Pathways by Fe-S Proteins.
Date: March 19–20, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
E:\FR\FM\25FEN1.SGM
25FEN1
]]>Agencies
[Federal Register Volume 80, Number 37 (Wednesday, February 25, 2015)]
[Notices]
[Pages 10129-10130]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-03779]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
HbF Induction Therapy for Sickle Cell Disease and Thalassemias
Description of Technology: Sickle cell disease and thalassemia are
hereditary disorders marked by the disruption in the pathways
responsible for carrying oxygen to red blood cells. Symptoms associated
with these disorders include anemia, jaundice, and severe pain. It has
been shown that mutations during the development of fetal to adult
hemoglobin can contribute to a delay in red blood cell maturity
underlying sickle cell disease. As a result, there has been an
increased focus on treatments that promote the induction of fetal
hemoglobin (HbF) to improve clinical symptoms and ameliorate the
severity of the diseases. Researchers at the National Institute of
Diabetes and Digestive and Kidney Diseases have identified methods of
increasing fetal hemoglobin by increasing the expression of Lin28 or
decreased expression of let-7 micro-RNAs. The lead inventor and
colleagues have developed novel lentiviral expression vectors
containing hemoglobin regulators under the control of erythroid-
specific promoters that can be used to increase Hbf expression without
affecting the maturity of red blood cells. In addition, they have
found, through the use of tough decoy inhibition of Let-7 micro-RNAs, a
selection of Let-7 genes with greater involvement in HbF expression.
This technology could lead to development of novel HbF induction
therapies that reactivate and reduce the aberrant pathologies
associated with human sickle-cell anemia and beta thalassemia.
Potential Commercial Applications:
Ex vivo and in vivo therapeutics for treatment of sickle-
cell anemia and beta thalassemias.
Potential use in combination with other transduction
methods for unique therapeutic strategies.
Competitive Advantages:
Reduced production of symptom-associated adult hemoglobin.
Lin28 overexpression at defined stage of hematopoietic
cell development.
Therapeutic increases in patient HbF expression at lower
viral titers than current direct transduction methods.
Improved safety and reduced toxicity as a result of
erythroid-specific expression.
Development Stage:
Early-stage
In vitro data available
In vivo data available (animal)
Inventors: Jeffery L. Miller, Yuanwei T. Lee, Jaira F. de
Vasconcellos, Colleen K. Byrnes (all of NIDDK)
Intellectual Property: HHS Reference No. E-249-2014/0--US
Provisional Application No. 62/046,247 filed September 5, 2014
Related Technology: HHS Reference No. E-456-2013/2--PCT Application
No. PCT/US2013/067811 filed October 31, 2013, which published as WO
2014/200557 on December 18, 2014
Licensing Contact: Vince Contreras, Ph.D.; 301-435-4711;
contrerasv@mail.nih.gov
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Diseases is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize this technology.
For collaboration opportunities, please contact Marguerite J. Miller at
millermarg@niddk.nih.gov or 301-496-9003.
T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-
Associated Pathologies
Description of Technology: Available for licensing are methods to
generate T cells responsive to multiple polyomaviruses. The resulting T
cell populations could be useful in treating immunosuppressed
individuals with polyomavirus infections or polyomavirus-associated
pathologies such as Merkel cell carcinoma (MCC), polyomavirus-
associated nephropathy (PVAN), hemorrhagic cystitis,
[[Page 10130]]
progressive multifocal leukoencephalopathy (PML), and trichodysplasia
spinulosa (TS). The methods could also be used to restore polyomavirus-
specific immunity in immunocompromised individuals.
Potential Commercial Applications: Immunotherapy for
immunosuppressed individuals with polyomavirus-associated pathologies.
Competitive Advantages: Methods allow development of polyomavirus
antigen-specific T cells.
Development Stage:
Early-stage
In vitro data available
Inventors: John A. Barrett (NHLBI), Dhanalakshmi Chinnasamy
(NHLBI), Pawel J. Muranski (NHLBI), Christopher B. Buck (NCI)
Intellectual Property: HHS Reference No. E-166-2014/0--US
Application No. 62/075,726 filed November 5, 2014
Related Technologies:
HHS Reference No. E-168-2011
HHS Reference No. E-549-2013
Licensing Contact: Patrick McCue, Ph.D.; 301-435-5560;
mccuepat@od.nih.gov
Collaborative Research Opportunity: The National Heart, Lung, and
Blood Institute is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate or commercialize methods to generate T cells responsive to
multiple polyomaviruses. For collaboration opportunities, please
contact Dr. Vincent Kolesnitchenko at kolesniv@nhlbi.nih.gov.
\89\Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and
Associated Methods
Description of Technology: This technology relates to a Zirconium-
89 (\89\Zr)-oxine complex for cell labeling, tracking of labeled cells
by whole-body positron emission tomography/computed tomography (PET/CT)
imaging, and associated methods. A long half-life of \89\Zr (78.4
hours), high sensitivity of PET and absence of background signal in the
recipient enable tracking cells over a week using low levels of
labeling radioactivity, without causing cellular toxicity. The \89\Zr-
oxine complex is synthesized quickly by mixing components at room
temperature and produces high yields. Cell labeling is achieved by a
short, room temperature incubation. The \89\Zr-oxine complex is capable
of labeling a wide range of cell types of therapeutic or pathogenic
relevance (natural, disease, engineered cells), independent of factors
such as cell cycle or receptor expression. The label is retained during
cell division. \89\Zr-oxine labeled cells can also be easily cross
labeled (for example, optically or magnetically) for multi-modality
imaging and analysis. Labeled cell migration and kinetics can be
analyzed and quantified in vivo over a week, improving research
strategies and ability to develop and improve cell therapies and
diagnostics.
Potential Commercial Applications: Cell therapies and diagnostics.
Competitive Advantages: Simple preparation, broadly applicable cell
label, high resolution imaging and monitoring over period of a week,
low toxicity, easily combined with labeling technologies and cell
therapies.
Development Stage: In vivo data available (animal).
Inventors: Noriko Sato (NCI), Haitao Wu (NHLBI), Gary L. Griffiths
(NCI), Peter L. Choyke (NCI)
Publications:
1. Sato N, et al. Generation and use of long-lasting cell labeling
agent for positron emission tomography (PET) imaging. J Nucl Med. May
2014; 55 (Supplement 1):273.
2. Sato N, et al. \89\Zr-oxine complex positron emission tomography
(PET) cell imaging for monitoring cell-based therapies. Radiology,
2015, In press.
Intellectual Property: HHS Reference No. E-080-2014/0--US Patent
Application No. 61/973,706 filed April 1, 2014
Licensing Contact: Edward (Tedd) Fenn; 424-297-0336;
Tedd.fenn@nih.gov
Collaborative Research Opportunity: The National Cancer Institute
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate or commercialize
cell labeling, cell tracking, cell trafficking, cell-based therapy, PET
imaging. For collaboration opportunities, please contact John D. Hewes,
Ph.D. at john.hewes@nih.gov or 240-276-5515.
Dated: February 18, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-03779 Filed 2-24-15; 8:45 am]
BILLING CODE 4140-01-P
